Sign up
Pharma Capital

IXICO's Derek Hill hails potential of wrist-worn sensors in neuroscience

Derek Hill, president of regulatory science and external relations at IXICO Plc (LON:IXI), discusses with Proactive their two-year contract worth £500,000 with a top-15 pharma company to deploy their wrist-worn sensors in a Phase II clinical trial.

It is the company’s first commercial agreement using the devices. They will be used along with artificial intelligence data analytics algorithms to monitor sleep disturbance in around 300 people.


View full IXI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.